Cargando…

BECN1 and BIM interactions with MCL-1 determine fludarabine resistance in leukemic B cells

The purine analog fludarabine (Fd) is an essential therapeutic for chronic lymphocytic leukemia (CLL). Innate or acquired resistance to Fd is a significant clinical problem and is largely mediated by increased expression of BCL-2 family members. The antiapoptotic BCL-2 family proteins inhibit both a...

Descripción completa

Detalles Bibliográficos
Autores principales: Sharma, A, Singh, K, Mazumder, S, Hill, B T, Kalaycio, M, Almasan, A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3674362/
https://www.ncbi.nlm.nih.gov/pubmed/23681223
http://dx.doi.org/10.1038/cddis.2013.155
_version_ 1782272361389621248
author Sharma, A
Singh, K
Mazumder, S
Hill, B T
Kalaycio, M
Almasan, A
author_facet Sharma, A
Singh, K
Mazumder, S
Hill, B T
Kalaycio, M
Almasan, A
author_sort Sharma, A
collection PubMed
description The purine analog fludarabine (Fd) is an essential therapeutic for chronic lymphocytic leukemia (CLL). Innate or acquired resistance to Fd is a significant clinical problem and is largely mediated by increased expression of BCL-2 family members. The antiapoptotic BCL-2 family proteins inhibit both apoptosis and autophagy, therefore, downregulation of antiapoptotic BCL-2 family proteins and enhanced autophagy must coexist in cells dying in response to an apoptosis inducing therapeutic. However, in the drug-resistant cells that have an increased dependence on antiapoptotic proteins, whether autophagy is also inhibited remains unclear. Here, we examined the role of the BCL-2 family in regulating cell death and autophagy in leukemic cell lines and their derivative isogenic Fd-resistant (FdR) cells. MCL-1 degradation following Fd treatment freed the proapoptotic effectors BIM and BECN1, thus leading to cell death-associated autophagy in Fd-sensitive cells. However, in FdR cells, low BIM expression and BECN1 sequestration by MCL-1 prevented cell death. Consistently, in sensitive cells inhibition of apoptosis using siBIM and of both the early-phase autophagy nucleation steps by siBECN1, shATG7 or 3-methyladenine and the late-phase autophagy by shLAMP2, significantly reduced Fd-induced cell death. Paradoxically, FdR cells were addicted to basal autophagy, which was dependent on AMP-activated protein kinase (AMPK) but not BECN1. Moreover, in FdR cells, inhibition of autophagy by shLAMP2, but not siBECN1, enhanced cell death. The BH3-mimetic obatoclax released BIM and BECN1 from MCL-1 in Fd-sensitive and BECN1 from MCL-1 in FdR cells, and was effective at killing both Fd-sensitive and - resistant leukemic cells, including primary CLL cells. Therefore, a differential regulation of autophagy through BECN1 and AMPK signaling in Fd-sensitive and - resistant cells determines the different possible outcomes of autophagy inhibition. These findings suggest effective means to overcome Fd resistance by induction of BIM-dependent apoptosis and activation of BECN1-dependent autophagy.
format Online
Article
Text
id pubmed-3674362
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-36743622013-06-06 BECN1 and BIM interactions with MCL-1 determine fludarabine resistance in leukemic B cells Sharma, A Singh, K Mazumder, S Hill, B T Kalaycio, M Almasan, A Cell Death Dis Original Article The purine analog fludarabine (Fd) is an essential therapeutic for chronic lymphocytic leukemia (CLL). Innate or acquired resistance to Fd is a significant clinical problem and is largely mediated by increased expression of BCL-2 family members. The antiapoptotic BCL-2 family proteins inhibit both apoptosis and autophagy, therefore, downregulation of antiapoptotic BCL-2 family proteins and enhanced autophagy must coexist in cells dying in response to an apoptosis inducing therapeutic. However, in the drug-resistant cells that have an increased dependence on antiapoptotic proteins, whether autophagy is also inhibited remains unclear. Here, we examined the role of the BCL-2 family in regulating cell death and autophagy in leukemic cell lines and their derivative isogenic Fd-resistant (FdR) cells. MCL-1 degradation following Fd treatment freed the proapoptotic effectors BIM and BECN1, thus leading to cell death-associated autophagy in Fd-sensitive cells. However, in FdR cells, low BIM expression and BECN1 sequestration by MCL-1 prevented cell death. Consistently, in sensitive cells inhibition of apoptosis using siBIM and of both the early-phase autophagy nucleation steps by siBECN1, shATG7 or 3-methyladenine and the late-phase autophagy by shLAMP2, significantly reduced Fd-induced cell death. Paradoxically, FdR cells were addicted to basal autophagy, which was dependent on AMP-activated protein kinase (AMPK) but not BECN1. Moreover, in FdR cells, inhibition of autophagy by shLAMP2, but not siBECN1, enhanced cell death. The BH3-mimetic obatoclax released BIM and BECN1 from MCL-1 in Fd-sensitive and BECN1 from MCL-1 in FdR cells, and was effective at killing both Fd-sensitive and - resistant leukemic cells, including primary CLL cells. Therefore, a differential regulation of autophagy through BECN1 and AMPK signaling in Fd-sensitive and - resistant cells determines the different possible outcomes of autophagy inhibition. These findings suggest effective means to overcome Fd resistance by induction of BIM-dependent apoptosis and activation of BECN1-dependent autophagy. Nature Publishing Group 2013-05 2013-05-16 /pmc/articles/PMC3674362/ /pubmed/23681223 http://dx.doi.org/10.1038/cddis.2013.155 Text en Copyright © 2013 Macmillan Publishers Limited http://creativecommons.org/licenses/by-nc-nd/3.0/ This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/
spellingShingle Original Article
Sharma, A
Singh, K
Mazumder, S
Hill, B T
Kalaycio, M
Almasan, A
BECN1 and BIM interactions with MCL-1 determine fludarabine resistance in leukemic B cells
title BECN1 and BIM interactions with MCL-1 determine fludarabine resistance in leukemic B cells
title_full BECN1 and BIM interactions with MCL-1 determine fludarabine resistance in leukemic B cells
title_fullStr BECN1 and BIM interactions with MCL-1 determine fludarabine resistance in leukemic B cells
title_full_unstemmed BECN1 and BIM interactions with MCL-1 determine fludarabine resistance in leukemic B cells
title_short BECN1 and BIM interactions with MCL-1 determine fludarabine resistance in leukemic B cells
title_sort becn1 and bim interactions with mcl-1 determine fludarabine resistance in leukemic b cells
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3674362/
https://www.ncbi.nlm.nih.gov/pubmed/23681223
http://dx.doi.org/10.1038/cddis.2013.155
work_keys_str_mv AT sharmaa becn1andbiminteractionswithmcl1determinefludarabineresistanceinleukemicbcells
AT singhk becn1andbiminteractionswithmcl1determinefludarabineresistanceinleukemicbcells
AT mazumders becn1andbiminteractionswithmcl1determinefludarabineresistanceinleukemicbcells
AT hillbt becn1andbiminteractionswithmcl1determinefludarabineresistanceinleukemicbcells
AT kalayciom becn1andbiminteractionswithmcl1determinefludarabineresistanceinleukemicbcells
AT almasana becn1andbiminteractionswithmcl1determinefludarabineresistanceinleukemicbcells